scholarly article | Q13442814 |
P356 | DOI | 10.1002/IBD.3780040415 |
P698 | PubMed publication ID | 9836088 |
P2093 | author name string | A Kornbluth | |
P433 | issue | 4 | |
P921 | main subject | Crohn's disease | Q1472 |
P304 | page(s) | 328-329 | |
P577 | publication date | 1998-11-01 | |
P1433 | published in | Inflammatory Bowel Diseases | Q15749161 |
P1476 | title | Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference | |
P478 | volume | 4 |
Q88946789 | A new CHO (Chinese hamster ovary)-derived cell line expressing anti-TNFα monoclonal antibody with biosimilar potential |
Q28571862 | A pharmacologically active monoclonal antibody against the human melanocortin-4 receptor: effectiveness after peripheral and central administration |
Q26865009 | A review of the impact of biologics on surgical complications in Crohn's disease |
Q37233054 | Antibodies against G-protein coupled receptors: novel uses in screening and drug development |
Q35537181 | BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment |
Q82296132 | Cerebral tubercular lesions in a patient treated with infliximab for Crohn's disease |
Q92358318 | Etiology and Management of Lack or Loss of Response to Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease |
Q37725721 | Golimumab and malignancies: true or false association? |
Q37606758 | Incidences of serious infections and tuberculosis among patients receiving anti-tumor necrosis factor-α therapy |
Q40046093 | Infliximab Therapy Leading to Pulmonary Tuberculosis in a Patient With Negative Interferon γ Release Assay (IGRA)-Based QuantiFERON Gold Test |
Q94325458 | Infliximab for the treatment of hidradenitis suppurativa |
Q35596600 | Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County |
Q74622961 | Murine monoclonal anti-tNF antibody administration has a beneficial effect on inflammatory bowel disease that develops in IL-10 knockout mice |
Q42934166 | Recent developments in the surgical management of perianal fistula for Crohn's disease. |
Q33555986 | Restoring the balance: immunotherapeutic combinations for autoimmune disease |
Q92918204 | Single-Molecule 3D Images of "Hole-Hole" IgG1 Homodimers by Individual-Particle Electron Tomography |
Q41524475 | Strictureplasty for Treatment of Crohn's Disease: an ACS-NSQIP Database Analysis |
Q55287141 | TNF-α blockade impairs in vitro tuberculous granuloma formation and down modulate Th1, Th17 and Treg cytokines. |
Q64969854 | Targeting mucosal healing in Crohn's disease: what the clinician needs to know. |
Q64980007 | The 'totality-of-the-evidence' approach in the development of PF-06438179/GP1111, an infliximab biosimilar, and in support of its use in all indications of the reference product. |
Q92276623 | The Expanding Role of Anti-IL-12 and/or Anti-IL-23 Antibodies in the Treatment of Inflammatory Bowel Disease |
Q48059378 | The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions. |
Q37540190 | The Role of Biosimilars in Inflammatory Bowel Disease |
Q60017517 | The current state of the art for biological therapies and new small molecules in inflammatory bowel disease |
Q30304487 | The relationship between infliximab treatment and lymphoma in Crohn's disease |
Q40629396 | Trends in the Surgical Management of Crohn's Disease. |
Q81795147 | Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients |
Search more.